Latigo Biotherapeutics
PrivateLast Round
Series B
Mar 17, 2025
Total Funding Raised
$285M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Latigo Biotherapeutics is a biotechnology company developing innovative non-opioid pain medicines that target pain at its source to provide effective, rapid-acting relief without the risk of addiction.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Latigo Biotherapeutics Comparables
Compare Latigo Biotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Centrexion Therapeutics | 87% | |
| Tafalgie Therapeutics | 86% | |
| South Rampart Pharma, Inc. | 84% |
Latigo Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Mar 17, 2025 | ||||
| Series A | Feb 14, 2024 |
Latigo Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Westlake Village BioPartners | Series B, Series A |
| Cormorant Asset Management | Series B |
| Corner Ventures | Series A |
| Blue Owl Capital | Series B |
| Deep Track Capital | Series B |
| 5AM Ventures | Series B, Series A |
| Foresite Capital | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 19, 2026
Monthly visitors grew 31% MoM, from 4.2K to 5.5K.
- May 16, 2026
Monthly visitors grew 63% MoM, reaching 1.4K.
Recent news
Latest coverage and updates
- is_developingJul 20, 2026
Latigo Biotherapeutics, Inc. is developing non-opioid pain reliever acting as an oral Nav1.8 inhibitor.
- goes_publicJul 19, 2026
Latigo Biotherapeutics, Inc. was planning to go public on Jul 19th '26.
Latigo Biotherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Latigo Biotherapeutics's valuation, stock price, and market status.
Is Latigo Biotherapeutics a public or private company?
Latigo Biotherapeutics is a private company.
What is the current stock price of Latigo Biotherapeutics?
Latigo Biotherapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Latigo Biotherapeutics worth (valuation)?
Valuation information for Latigo Biotherapeutics is not publicly available.
Can I buy Latigo Biotherapeutics stock?
Latigo Biotherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Latigo Biotherapeutics's last funding round?
Latigo Biotherapeutics's most recent funding round was Series B on March 17, 2025.
Who are the main investors in Latigo Biotherapeutics?
Key investors in Latigo Biotherapeutics include Westlake Village Biopartners, Blue Owl Capital, 5AM Ventures, Foresite Capital, Foresite Labs.
Will Latigo Biotherapeutics IPO soon?
No public IPO plans have been announced for Latigo Biotherapeutics.
How can I track Latigo Biotherapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Latigo Biotherapeutics's secondary market activity and sign up for updates.